Targovax ASA
Records under this name other than the patents Targovax ASA holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Showing 1 to 9 of 9 · Back to Targovax ASA
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,456,457 | Peptide mixture Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,596,239 | Peptide mixture Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,335,473 | Peptide mixture Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,775,892 | Peptide mixture Formerly held Lapsed on the fee record Ended Oct 3, 2025 · From the USPTO record | Lapsed on the fee record | Ended Oct 3, 2025 | From the USPTO record |
| US 9,757,439 | Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent Formerly held Lapsed on the fee record Ended Sep 12, 2025 · From the USPTO record | Lapsed on the fee record | Ended Sep 12, 2025 | From the USPTO record |
| US 10,940,203 | Combining adenovirus and checkpoint inhibitors for treating cancer Lapsed on the fee record Ended Mar 9, 2025 · From the USPTO record | Lapsed on the fee record | Ended Mar 9, 2025 | From the USPTO record |
| US 9,345,787 | Adenoviral vectors and methods and uses related thereto Lapsed on the fee record Ended May 24, 2024 · From the USPTO record | Lapsed on the fee record | Ended May 24, 2024 | From the USPTO record |
| US 9,410,129 | Recombinant serotype 5 (Ad5) adenoviral vectors Lapsed on the fee record Ended Aug 9, 2020 · From the USPTO record | Lapsed on the fee record | Ended Aug 9, 2020 | From the USPTO record |
| US 5,961,978 | Therapeutically useful peptides and peptide fragments Term ended Term ended no later than Oct 5, 2019 · Low confidence | Term ended | Term ended no later than Oct 5, 2019 | Low confidence |